RhumbLine Advisers’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

RhumbLine Advisers’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-35,135	Closed	-$97K	–	3306
2022 Q1	$97K	Sell	35,135 -2,932	-8%	-$9.22K	﹤0.01%	2892
2021 Q4	$177K	Sell	38,067 -617	-2%	-$3.86K	﹤0.01%	2858
2021 Q3	$329K	Buy	38,684 +1,435	+4%	+$20.3K	﹤0.01%	2733
2021 Q2	$611K	Buy	37,249 +375	+1%	+$7.58K	﹤0.01%	2473
2021 Q1	$814K	Sell	36,874 -10	-0%	-$273	﹤0.01%	2284
2020 Q4	$1.14M	Buy	36,884 +6,433	+21%	+$163K	﹤0.01%	2080
2020 Q3	$619K	Buy	30,451 +8,191	+37%	+$144K	﹤0.01%	2189
2020 Q2	$342K	Buy	22,260 +9,922	+80%	+$114K	﹤0.01%	2518
2020 Q1	$95K	Buy	12,338 +1,270	+11%	+$15.5K	﹤0.01%	2789
2019 Q4	$158K	Buy	11,068 +278	+3%	+$4.3K	﹤0.01%	2805
2019 Q3	$162K	Buy	+10,790	New	+$168K	﹤0.01%	2797

Other funds holding TCRR

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

RhumbLine Advisers's TCRR Position: Q2 2022 in Review

RhumbLine Advisers sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2022, closing a stake of 35,135 shares — an estimated $97K sold.

RhumbLine Advisers first reported a position in TCRR in Q3 2019 and held it in 11 quarters. The position peaked at $1.14M in Q4 2020. 83 funds tracked by Wall St. Rank hold TCRR as of Q2 2022.

RhumbLine Advisers reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
RhumbLine Advisers sold 35,135 TCR2 Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $97K.
RhumbLine Advisers first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2019 and held it in 11 quarters.
RhumbLine Advisers's TCR2 Therapeutics Inc. Common Stock position peaked at $1.14M in Q4 2020.
83 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.